<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Apher</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Apher</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1098-1101</journal-id><journal-id journal-id-type="publisher-id">JCA</journal-id><journal-title-group><journal-title>Journal of Clinical Apheresis</journal-title></journal-title-group><issn pub-type="ppub">0733-2459</issn><issn pub-type="epub">1098-1101</issn><publisher><publisher-name>John Wiley &#x00026; Sons, LLC.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7361338</article-id><article-id pub-id-type="doi">10.1002/jca.21806</article-id><article-id pub-id-type="publisher-id">JCA21806</article-id><article-categories><subj-group subj-group-type="overline"><subject>Concise Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Concise Review</subject></subj-group></article-categories><title-group><article-title>Convalescent plasma therapy in patients with <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19</article-title><alt-title alt-title-type="left-running-head">Yi&#x0011f;eno&#x0011f;lu et al.</alt-title></title-group><contrib-group><contrib id="jca21806-cr-0001" contrib-type="author" corresp="yes"><name><surname>Yi&#x0011f;eno&#x0011f;lu</surname><given-names>Tu&#x0011f;&#x000e7;e Nur</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9962-8882</contrib-id><xref ref-type="aff" rid="jca21806-aff-0001">
<sup>1</sup>
</xref><address><email>dr.nuryigenoglu@gmail.com</email></address></contrib><contrib id="jca21806-cr-0002" contrib-type="author"><name><surname>Hac&#x00131;bekiro&#x0011f;lu</surname><given-names>Tuba</given-names></name><xref ref-type="aff" rid="jca21806-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jca21806-cr-0003" contrib-type="author"><name><surname>Berber</surname><given-names>&#x00130;lhami</given-names></name><xref ref-type="aff" rid="jca21806-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jca21806-cr-0004" contrib-type="author"><name><surname>Dal</surname><given-names>Mehmet Sinan</given-names></name><xref ref-type="aff" rid="jca21806-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jca21806-cr-0005" contrib-type="author"><name><surname>Ba&#x0015f;t&#x000fc;rk</surname><given-names>Abd&#x000fc;lkadir</given-names></name><xref ref-type="aff" rid="jca21806-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jca21806-cr-0006" contrib-type="author"><name><surname>Namdaro&#x0011f;lu</surname><given-names>Sinem</given-names></name><xref ref-type="aff" rid="jca21806-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jca21806-cr-0007" contrib-type="author"><name><surname>Korkmaz</surname><given-names>Serdal</given-names></name><xref ref-type="aff" rid="jca21806-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jca21806-cr-0008" contrib-type="author"><name><surname>Ulas</surname><given-names>Turgay</given-names></name><xref ref-type="aff" rid="jca21806-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jca21806-cr-0009" contrib-type="author"><name><surname>Dal</surname><given-names>Tuba</given-names></name><xref ref-type="aff" rid="jca21806-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="jca21806-cr-0010" contrib-type="author"><name><surname>Erkurt</surname><given-names>Mehmet Ali</given-names></name><xref ref-type="aff" rid="jca21806-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jca21806-cr-0011" contrib-type="author"><name><surname>Turgut</surname><given-names>Burhan</given-names></name><xref ref-type="aff" rid="jca21806-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jca21806-cr-0012" contrib-type="author"><name><surname>Altunta&#x0015f;</surname><given-names>Fevzi</given-names></name><xref ref-type="aff" rid="jca21806-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jca21806-aff-0010">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="jca21806-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center</named-content>
<institution>University of Health Sciences</institution>
<city>Ankara</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Sakarya University</institution>
<named-content content-type="country-part">Sakarya</named-content>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Inonu University</institution>
<city>Malatya</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Selcuk University</institution>
<city>Konya</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Bozyaka Training and Research Hospital, Department of Hematology</named-content>
<institution>University of Health Sciences</institution>
<city>Izmir</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Kayseri Training and Research Hospital, Department of Hematology</named-content>
<institution>University of Health Sciences</institution>
<city>Kayseri</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Near East University</institution>
<city>Nicosia</city>
<country country="CY">Cyprus</country>
</aff><aff id="jca21806-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Clinical Microbiology</named-content>
<institution>Ankara Y&#x00131;ld&#x00131;r&#x00131;m Beyaz&#x00131;t University</institution>
<city>Ankara</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Nam&#x00131;k Kemal University</institution>
<city>Tekirda&#x0011f;</city>
<country country="TR">Turkey</country>
</aff><aff id="jca21806-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">School of Medicine, Department of Internal Medicine, Division of Hematology</named-content>
<institution>Ankara Y&#x00131;ld&#x00131;r&#x00131;m Beyaz&#x00131;t University</institution>
<city>Ankara</city>
<country country="TR">Turkey</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Tu&#x0011f;&#x000e7;e Nur Yi&#x0011f;eno&#x0011f;lu, Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.<break/>
Email: <email>dr.nuryigenoglu@gmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>7</month><year>2020</year></pub-date><elocation-id>10.1002/jca.21806</elocation-id><history><date date-type="received"><day>23</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>04</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley Periodicals LLC. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 Wiley Periodicals LLC.</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JCA-9999-na.pdf"/><abstract><title>Abstract</title><p>There are currently no licensed vaccines or therapeutics for COVID&#x02010;19. Anti&#x02010;SARS CoV&#x02010;2 antibody&#x02010;containing plasmas, obtained from the recovered individuals who had confirmed COVID&#x02010;19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID&#x02010;19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID&#x02010;19. CP may be an adjunctive treatment option to the anti&#x02010;viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200&#x02010;600&#x02009;mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID&#x02010;19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jca21806-kwd-0001">convalescent plasma</kwd><kwd id="jca21806-kwd-0002">COVID&#x02010;19</kwd><kwd id="jca21806-kwd-0003">SARS CoV&#x02010;2</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><page-count count="7"/><word-count count="4862"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.5 mode:remove_FC converted:15.07.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="jca21806-cit-9001">
<string-name>
<surname>Yi&#x0011f;eno&#x0011f;lu</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Hac&#x00131;bekiro&#x0011f;lu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Berber</surname>
<given-names>&#x00130;</given-names>
</string-name>, et al. <article-title>Convalescent plasma therapy in patients with <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19</article-title>. <source xml:lang="en">J Clin Apher</source>. <year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/jca.21806</pub-id>
</mixed-citation>
</p></notes></front><body id="jca21806-body-0001"><sec id="jca21806-sec-0001"><label>1</label><title>INTRODUCTION</title><p>At the end of 2019, pneumonia patients with an unidentified cause were started to be observed in Wuhan, Hubei Province, China.<xref rid="jca21806-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> After the genetic analysis of the virus, it was understood that these pneumonia cases were caused by the 2019 Novel Coronavirus (2019&#x02010;nCoV).<xref rid="jca21806-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> On 11 February 2020; the disease was officially named as COVID&#x02010;19, by the World Health Organization (WHO).<xref rid="jca21806-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> This novel coronavirus was named as SARS&#x02010;CoV&#x02010;2 by the International Committee on Taxonomy of Viruses.<xref rid="jca21806-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> It was declared a pandemic by the WHO on 11 March 2020. As of 17 April 2020, in the worldwide, there have been 2&#x02009;175&#x02009;130 confirmed cases of COVID&#x02010;19, including 145&#x02009;184 deaths, as reported to WHO.<xref rid="jca21806-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> The mortality rate of COVID&#x02010;19 is higher than the mortality rate of seasonal influenza in which the mortality rate is reported usually less than 0.1%.<xref rid="jca21806-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> Patients with any comorbidity and/or older age are associated with poorer clinical outcomes than younger patients or those without any comorbidity. As the number of comorbidities increases, the clinical outcome gets worse. Smoking, chronic obstructive pulmonary disease, diabetes, hypertension, cardiovascular diseases, and malignancy are reported to be the risk factors for severe COVID&#x02010;19 and increased mortality.<xref rid="jca21806-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Although there are clinical trials regarding the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID&#x02010;19. Because of the higher mortality rate and the high number of infected cases, it is important to find a treatment in a short time.</p><p>Passive antibody therapy involves administering antibodies against a particular agent to a susceptible individual in order to protect or treat an infectious disease associated with this agent. On the contrary, active vaccination requires stimulation of an immune response that takes time to develop. Therefore, passive antibody administration is the only way to immunize susceptible people immediately. Passive antibody therapy has a history going back to the 1890s and was the only method of treating some infectious diseases before the development of antimicrobial therapy in the 1940s.<xref rid="jca21806-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> Currently, passive antibody therapy is mainly consisting of pooled immunoglobulin preparations that includes high concentrations of antibodies. On the other hand, CP has been used emergently in epidemics where there is insufficient time to produce immunoglobulin preparations.<xref rid="jca21806-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>
</p><p>Anti&#x02010;SARS COV&#x02010;2 antibody containing plasma, obtained from the recovered individuals who had confirmed COVID&#x02010;19, have been started to be collected by apheresis devices and stored in blood banks in some countries such as Turkey and the United States of America in hopes of reducing mortality rates and reduce the need of intensive care. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID&#x02010;19.</p></sec><sec id="jca21806-sec-0002"><label>2</label><title>TREATMENT OF INFECTIOUS DISEASES WITH CONVALESCENT PLASMA: HISTORICAL EXAMPLES</title><p>In the past, plasma&#x02010;mediated treatments have been used against many pathogens. Passive immunization obtained from sheep serum against diphtheria toxin was first given to a child with diphtheria in 1891 and saved his life. German scientist Emil Adolf von Behring received the 1901 Nobel Prize for his discovery of passive immunization against diphtheria toxin. CPs have been used in epidemics of viral infections like poliomyelitis, measles, mumps and flu.<xref rid="jca21806-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>
</p><p>Experience in the use of CP against coronavirus was obtained from Severe Acute Respiratory Syndrome 1 (SARS&#x02010;COV&#x02010;1) outbreaks in 2003. In the retrospective non&#x02010;randomized study conducted by Soo et al, 40 SARS patients refractory to ribavirin and 1.5 g of pulsed methylprednisolone received either 200&#x02010;400&#x02009;mL CP (n = 19) or a further dose of pulsed methylprednisolone (n = 21). In patients who received CP, higher discharge rate up to 22&#x02009;days from the hospital (77.8% vs 23%; <italic>P</italic> = .004) and lower mortality rate (0% vs 23.8%; <italic>P</italic> = .049) was observed compared to the patients who received steroids. The authors also observed that patients receiving CP after day 16 had a poor clinical response and concluded that CP administration was more effective when given early in the course of the disease.<xref rid="jca21806-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> In Taiwan, Yeh et al reported three healthcare workers with SARS&#x02010;COV&#x02010;1, who had failed to respond to steroids, ribavirin, intravenous immunoglobulin and protease inhibitors, were treated with 500&#x02009;mL CP. All of the patients survived after CP transfusion.<xref rid="jca21806-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Besides, Cheng et al evaluated the efficacy of CP in the treatment of patients with SARS in 2003 and found a higher day&#x02010;22 discharge rate among patients who received CP before day 14 of illness.<xref rid="jca21806-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>
</p><p>CP was also used in the West African Ebola epidemic in 2013. Eighty&#x02010;four patients received 500&#x02009;mL of CP. When compared to the historical control group, the CP group had a shorter duration of symptoms than did the control group. From day 3 to day 16 after diagnosis, the risk of death was 31% in the CP group and 38% in the control group. Even though the transfusion of up to 500&#x02009;mL CP improved the symptoms, no significant survival benefit was observed.<xref rid="jca21806-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Treatment with CP was also reported in three patients with Middle East Respiratory Syndrome (MERS) in South Korea. In this study, 3 of 13 MERS patients with respiratory failure received 4 CP infusions from recovered MERS&#x02010;CoV&#x02010;infected patients, and only two of them showed neutralizing activity. After the infusion of CP with a neutralizing activity titer of 1:80, serological response was achieved but no response was achieved after the infusions of CP with a neutralizing activity titer of 1:40.<xref rid="jca21806-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="jca21806-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>
</p></sec><sec id="jca21806-sec-0003"><label>3</label><title>TREATMENT OF <styled-content style="fixed-case" toggle="no">COVID</styled-content>&#x02010;19 WITH CONVALESCENT PLASMA</title><p>CP has been used in the recent global outbreak for the treatment of patients with COVID&#x02010;19 in China. In the study conducted by Shen et al, 5 critically ill COVID&#x02010;19 patients refractory to steroid and antiviral treatment, received 400&#x02009;mL CP from 5 different donors. All the donors had SARS&#x02010;CoV&#x02010;2&#x02010;specific ELISA antibody titer higher than 1:1000; and neutralizing antibody titer greater than 40. After CP transfusion; in 4 (80%) of 5 patients, the body temperature normalized within 3&#x02009;days; the Sequential Organ Failure Assessment Score decreased, and PaO<sub>2</sub>/FiO<sub>2</sub> increased within 12&#x02009;days (range, first 172&#x02010;276 and then 284&#x02010;366); viral loads decreased and became negative within 12&#x02009;days; ELISA and neutralizing antibody titers increased. After 12&#x02009;days, acute respiratory distress syndrome (ARDS) improved in 4 patients (80%); after 2&#x02009;weeks, 3 patients extubated; 3 of the 5 patients (60%) were discharged from the hospital and the other two patients were stable after 37&#x02009;days.<xref rid="jca21806-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> In a recent study, researchers treated 10 critically ill COVID&#x02010;19 patients with antiviral therapy and steroid, plus a dose of 200&#x02009;mL CP that had a neutralized antibody titer of at least 1:640. Researchers prospectively compared symptoms and laboratory findings 3&#x02009;days after CP infusion. Among all patients, CP was well tolerated. It significantly increased neutralizing antibodies at a high level; within 7&#x02009;days, viremia disappeared; clinical symptoms resolved rapidly in 3&#x02009;days. There was an improvement in lymphocyte count and in SaO<sub>2</sub>; on radiological examination, they reported that lung lesions changed significantly within 7&#x02009;days.<xref rid="jca21806-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> Although these studies involve a small number of patients, available information suggests that CP administration is safe and reduces the viral load.</p><p>On March 24, the American Food and Drug Administration (FDA) published a recommendation with the &#x0201c;COVID&#x02010;19 Convalescent Plasma Research &#x02010; Emergency&#x0201d; declaration. FDA stated that certain standards have been established for donation and that CP use is allowed for patients under certain conditions. Of note, FDA does not allow the use of CP for prophylaxis. With the &#x0201c;Blood Regulatory Network&#x0201d;, WHO suggested using CP when vaccines and anti&#x02010;viral drugs are not available in the treatment of critically ill patients with COVID&#x02010;19.<xref rid="jca21806-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>
</p><p>Turkish Ministry of Health allowed the use of CP in severe COVID&#x02010;19.<xref rid="jca21806-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Therapeutic apheresis centers licensed by the Ministry of Health and Turkish Red Crescent carry out activities for obtaining CP from donors. In Turkey, multidisciplinary working groups which have been attended by a large number of scientists were formed. These groups provide information and experience sharing among themselves by following donor selection, product standard, treatment management, patient&#x02010;donor follow&#x02010;up, and scientific developments in the world. CP administrations are carried out under the control of intensive care, infectious disease specialists and pulmonologists.</p></sec><sec id="jca21806-sec-0004"><label>4</label><title>CONVALESCENT PLASMA: THE MECHANISM OF ACTION</title><p>The exact mechanism of CP in COVID&#x02010;19 has not been clearly identified yet. However, previous studies revealed that the mechanism of action of CP in other viral infections such as Ebola virus and Respiratory Syncytial Virus is mainly viral neutralization. The other mechanisms are antibody&#x02010;induced cellular cytotoxicity, complement activation and phagocytosis. Neutralizing antibodies delivered with CP can provide control of the viral load. Non&#x02010;neutralizing antibodies may also contribute to prophylaxis and/or enhance recovery.<xref rid="jca21806-bib-0018" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="jca21806-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>
</p></sec><sec id="jca21806-sec-0005"><label>5</label><title>STEPS OF THE CONVALESCENT PLASMA COLLECTIONS</title><p>The regulations of every single step of CP collections is very important. Starting from assessment of donor to the administration of CP to the patients, all of the steps should be organized carefully and should be performed by experienced health workers.</p><sec id="jca21806-sec-0006"><label>5.1</label><title>Donor eligibility</title><p>The criteria for eligibility of CP donors may vary between countries. According to the FDA, individuals who meet the following criteria can be a CP donor<xref rid="jca21806-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>:<list list-type="order" id="jca21806-list-0001"><list-item id="jca21806-li-0001"><p>Recovered from COVID&#x02010;19, blood donor tests were done and suitable for donation;</p></list-item><list-item id="jca21806-li-0002"><p>Evidence of COVID&#x02010;19 documented by a laboratory test either by a diagnostic test (eg, nasopharyngeal swab) at the time of illness, or a positive serological test for SARS&#x02010;CoV&#x02010;2 antibodies after recovery, if prior diagnostic testing was not performed at the time COVID&#x02010;19 was suspected.</p></list-item><list-item id="jca21806-li-0003"><p>Complete resolution of symptoms at least 14&#x02009;days prior to donation.</p></list-item><list-item id="jca21806-li-0004"><p>Male donors, or female donors who have not been pregnant, or female donors who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.</p></list-item><list-item id="jca21806-li-0005"><p>When measurement of neutralizing antibody titers is available, neutralizing antibody titers of at least 1:160 is recommended. A titer of 1:80 may be considered acceptable if an alternative matched unit is not available.</p></list-item></list>
</p></sec><sec id="jca21806-sec-0007"><label>5.2</label><title>Pre&#x02010;donation evaluation of donors</title><p>Real&#x02010;time reverse transcriptase&#x02010;PCR (RT&#x02010;PCR) is currently a favored assay for the detection of coronavirus. However, RNA detectability was low in samples collected before day&#x02010;7 and during days 15&#x02010;39. For this reason, coronavirus pre&#x02010;donation screening tests should be supported by antibody detecting tests.<xref rid="jca21806-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> Each donor must meet all eligibility criteria and be evaluated by all test required for normal blood donation. Female donors with a history of pregnancy should be screened for HLA antibodies to minimize the risk of transfusion&#x02010;related acute lung injury (TRALI). In addition, a blood sample should be obtained for antibody testing before referring the donor to an apheresis procedure. Unfortunately, neutralizing antibody assays are not available in most centers. Quantitative assays (eg, ELISA) are available but commercially available assays have not been optimally validated. In addition, the relationship between total anti&#x02010;SARS&#x02010;CoV&#x02010;2 antibodies and neutralizing anti&#x02010;SARS&#x02010;CoV&#x02010;2 antibodies is not clear. There is also uncertainty as to whether total antibodies or subclasses (eg, IgM, IgG, or IgA) are the optimal measures, and which antigen is most informative.<xref rid="jca21806-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>, <xref rid="jca21806-bib-0022" ref-type="ref">
<sup>22</sup>
</xref> Limited data are currently available on the ELISAs. In a previous study, the efficacy of the antibody test for the detection of IgM and IgG, has shown a sensitivity and specificity of 88.7% and 90.6%, respectively. The antibody titer will differ according to the duration between the collection time and onset of infection. In previous studies, seroconversion has been observed to occur between 8 and 21&#x02009;days after the onset of symptoms.<xref rid="jca21806-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="jca21806-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="jca21806-bib-0024" ref-type="ref">
<sup>24</sup>
</xref>, <xref rid="jca21806-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> In a study conducted in 173 patients with COVID&#x02010;19, the seroconversion rate for total antibodies (Ab), IgM and IgG was 93.1%, 82.7%, and 64.7%, respectively. The median seroconversion time for total Ab, IgM and then IgG were day&#x02010;11, day&#x02010;12 and day&#x02010;14, separately. The presence of antibodies was &#x0003c;40% within 1&#x02010;week since onset but rapidly increased to 100.0% (total Ab), 94.3% (IgM), and 79.8% (IgG) since day&#x02010;15 after onset. RNA detectability decreased from 66.7% in samples collected before day&#x02010;7 to 45.5% during days 15&#x02010;39. The authors suggested that combining RNA and antibody detections significantly improved the sensitivity of diagnosis for COVID&#x02010;19 in the first 1&#x02010;week since onset.<xref rid="jca21806-bib-0026" ref-type="ref">
<sup>26</sup>
</xref> Currently, the findings that have been reported suggest that CPs that are collected &#x02265;14&#x02009;days after resolution of symptoms contain high titers of antibodies.<xref rid="jca21806-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="jca21806-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>, <xref rid="jca21806-bib-0024" ref-type="ref">
<sup>24</sup>
</xref>, <xref rid="jca21806-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> According to FDA if testing can be conducted, neutralizing antibody titers should be at least 1:160 but a titer of 1:80 may be considered acceptable if an alternative matched unit is not available.<xref rid="jca21806-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>
</p></sec><sec id="jca21806-sec-0008"><label>5.3</label><title>Donor recruitment</title><p>Blood centers may play a role in recruitment of donors in collaboration with partner hospitals. In Turkey, therapeutic apheresis centers licensed by the Ministry of Health and Turkish Red Crescent carry out activities for obtaining CP from donors.</p></sec><sec id="jca21806-sec-0009"><label>5.4</label><title>Collection of convalescent plasma at apheresis centers</title><p>Donors who have successfully completed pre&#x02010;donation evaluation are directed to the apheresis centers. CP should be collected by apheresis to take larger volumes in short intervals. Approximately 200&#x02010;600&#x02009;mL plasma can be collected with apheresis devices depending on the total blood volume of the donor. The collected plasma volume (excluding the anticoagulant solution) should not exceed 750&#x02009;mL for each procedure. With the consent of the donor, an appointment can be arranged for plasma donation again. The donation interval may vary between countries. CP is stored by freezing or applied within 6 hours without freezing. Freezing should be started within the first 6 hours after the apheresis process is completed. Plasma components should be labeled using the ISBT128 coding system for traceability. The collected products can be individually labeled as 200&#x02009;mL of divided ingredients and defined as 1 unit. Barcoded products should be stored at or below minus 18/25&#x000b0; in a separate storage cabinet. Appropriate patients can be given 200&#x02010;400&#x02009;mL of CP in accordance with the clinical research protocol. ABO blood group should preferably be compatible. For pathogen inactivation process; amotosalen&#x02009;+&#x02009;UV light, riboflavin&#x02009;+&#x02009;UV light, methylene blue or a solvent/detergent may be used. But we would like to highlight that there has been no study that compared Anti&#x02010;SARS&#x02010;CoV&#x02010;2 CP that had undergone pathogen inactivation process to those of not. In order to maximize transfusion safety, it is recommended that the CP should undergone pathogen inactivation process. It should be irradiated if it will be given to the patient without being frozen within 6 hours after the plasma collection. Otherwise, the frozen plasma does not need to be irradiated.</p></sec></sec><sec id="jca21806-sec-0010"><label>6</label><title>THE DOSE OF CONVALESCENT PLASMA</title><p>In the previous studies, the dosing of CP is highly variable. In clinical trials, one unit of plasma (200&#x02009;mL) has been planned for use for prophylaxis and one to two units have been planned for treatment. The antibodies' duration of efficacy is unknown but is estimated to last in weeks to a few months.<xref rid="jca21806-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="jca21806-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="jca21806-bib-0028" ref-type="ref">
<sup>28</sup>
</xref> In previous use of CP therapy in SARS, 5 mL/kg of plasma at a titer of 1:160 was used.<xref rid="jca21806-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> A quarter or half of the treatment dose was used for prophylactic purposes in earlier studies. According to linear proportionality, 3.125&#x02009;mL/kg of plasma with a titer of &#x0003e;1:64 would provide an equivalent immunoglobulin level to one&#x02010;quarter of 5 mL/kg plasma with a titer of 1:160.<xref rid="jca21806-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>
</p><p>In pediatric transfusions, dose by body weight should be used. COVID&#x02010;19 is rarely symptomatic in the pediatric age group. Therefore, every procedure in this age group should be performed within the scope of clinical research in cooperation with national and international health authorities.</p></sec><sec id="jca21806-sec-0011"><label>7</label><title>PATIENT SELECTION</title><p>There are several clinical trials that are ongoing that have very different eligibility criteria from the severely affected to post exposure individuals.<xref rid="jca21806-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> The patient selection may vary between countries. The FDA allowed the use of CP to patients who met the following criteria<xref rid="jca21806-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>:<list list-type="bullet" id="jca21806-list-0002"><list-item id="jca21806-li-0006"><p>Laboratory confirmed COVID&#x02010;19</p></list-item><list-item id="jca21806-li-0007"><p>Severe or immediately life&#x02010;threatening COVID&#x02010;19.</p><list list-type="bullet" id="jca21806-list-0003"><list-item id="jca21806-li-0008"><p>Severe disease is defined as one or more of the following:</p><list list-type="bullet" id="jca21806-list-0004"><list-item id="jca21806-li-0009"><p>Dyspnea,</p></list-item><list-item id="jca21806-li-0010"><p>Tachypnea&#x02009;&#x02265;&#x02009;30/min,</p></list-item><list-item id="jca21806-li-0011"><p>blood oxygen saturation&#x02009;&#x02264;&#x02009;93%,</p></list-item><list-item id="jca21806-li-0012"><p>PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x0003c;&#x02009;300,</p></list-item><list-item id="jca21806-li-0013"><p>lung infiltrates &#x0003e;50% within 24&#x02010;48&#x02009;hours</p></list-item></list></list-item><list-item id="jca21806-li-0014"><p>The life&#x02010;threatening disease is defined as one or more of the following:</p><list list-type="bullet" id="jca21806-list-0005"><list-item id="jca21806-li-0015"><p>respiratory failure,</p></list-item><list-item id="jca21806-li-0016"><p>septic shock,</p></list-item><list-item id="jca21806-li-0017"><p>multiple organ dysfunction</p></list-item></list></list-item></list></list-item></list>
</p></sec><sec id="jca21806-sec-0012"><label>8</label><title>PROPHYLAXIS</title><p>There is no clear indication and evidence of benefit by using CP for prophylaxis for those who have been exposed to SARS&#x02010;CoV&#x02010;2, this issue is still controversial and FDA does not allow the use of CP for prophylaxis outside of approved clinical trials.<xref rid="jca21806-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="jca21806-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> However, historically, it has been stated that passive antibody therapy is most effective when administered prophylactically or used early after the onset of symptoms.<xref rid="jca21806-bib-0030" ref-type="ref">
<sup>30</sup>
</xref>, <xref rid="jca21806-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> The new, phase 2&#x02010;3 trial is recruiting patients and still evaluating the use of post&#x02010;exposure prophylactic plasma in COVID&#x02010;19 patients who have had close contact exposure, but have not yet presented symptoms.<xref rid="jca21806-bib-0032" ref-type="ref">
<sup>32</sup>
</xref>
</p></sec><sec id="jca21806-sec-0013"><label>9</label><title>RISKS OF CONVALESCENT PLASMA</title><p>The risks of CP administration are similar to those of standard plasma. Infection with another infectious disease agent (viral transmission or bacterial contamination), immunological reactions such as serum disease, non&#x02010;hemolytic transfusion reactions (tremors, fever, urticaria), transfusion&#x02010;associated circulatory overload and TRALI can be observed.<xref rid="jca21806-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> No serious adverse events have been reported in any study of CP. Two observational studies during the SARS&#x02010;CoV&#x02010;1 outbreak did not report any complications related to CP.<xref rid="jca21806-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> In developed countries, for HIV, hepatitis B and hepatitis C viruses, the risk of transfusion&#x02010;transmissible infection is less than one infection per two million donations.<xref rid="jca21806-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> The risk of TRALI is generally less than one for every 5000 transfused units, but in COVID&#x02010;19, the risk of TRALI is one of the major concerns about CP because most of the critically ill patients have ARDS and disseminated intravascular coagulation. Both of these situations are risk factors for the development of TRALI.<xref rid="jca21806-bib-0035" ref-type="ref">
<sup>35</sup>
</xref> Specific risk about Anti&#x02010;SARS&#x02010;CoV&#x02010;2 CP is transfusion&#x02010;transmitted SARS&#x02010;CoV&#x02010;2. This remains theoretical because there has been no report of SARS&#x02010;CoV&#x02010;2 transmission by blood transfusion. This risk is particularly important in prophylactic use since critically ill patients are already infected. In addition, only 1% of symptomatic patients have been reported to have detectable SARS&#x02010;CoV&#x02010;2 RNA in their blood.<xref rid="jca21806-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>, <xref rid="jca21806-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> Between January 25 to March 4, 2020; 2430 blood donations were screened in Wuhan and only one (0.04%) donor was found to be positive for SARS&#x02010;CoV&#x02010;2 RNA. Between December 21 to January 22, 2020; 4995 blood donations were screened and a second (0.02%) donor was found to be positive for SARS&#x02010;CoV&#x02010;2 RNA.<xref rid="jca21806-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> The other theoretical risk of CP is an antibody&#x02010;dependent enhancement (ADE). Antibodies that developed during a previous infectious disease caused by a different viral serotype may exacerbate clinical severity.<xref rid="jca21806-bib-0039" ref-type="ref">
<sup>39</sup>
</xref> Previous infection with other types of coronavirus may arise the concern about the risk of ADE in COVID&#x02010;19 and the geographic variation in disease severity may be attributed to this mechanism.<xref rid="jca21806-bib-0040" ref-type="ref">
<sup>40</sup>
</xref> In the current pandemic, there has been no report about the worsening of the clinical situation that has been attributed to ADE after CP infusion. Similarly, there has been no report about ADE after the use of CP for SARS and MERS. The other theoretical risk of CP is the attenuation of the development of a natural immune response, especially when administered for prophylaxis. CP treatment is recommended only in academic or comprehensive centers that can manage potential treatment&#x02010;related complications, such as TRALI.</p><p>In conclusion, SARS&#x02010;CoV&#x02010;2 continues to spread worldwide. The exact treatment of COVID&#x02010;19 disease is currently unknown. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID&#x02010;19. At least preliminary results of multicentre randomized controlled clinical trials should be waited. Meanwhile, in this pandemic, scientists should be encouraged to collaborate on common research protocols, rather than conducting independent researches. International multicenter randomized controlled trials are needed. CP use should be encouraged to be made within the scope of clinical trials in cooperation with national and international health authorities.</p></sec><sec sec-type="COI-statement" id="jca21806-sec-0015"><title>CONFLICT OF INTEREST</title><p>The authors have no conflicts of interest to disclose.</p></sec></body><back><ack id="jca21806-sec-0014"><title>ACKNOWLEDGEMENTS</title><p>There is no acknowledgement.</p></ack><ref-list id="jca21806-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jca21806-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jca21806-cit-0001">
<string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Early transmission dynamics in Wuhan, China, ofNovel coronavirus&#x02010;infected pneumonia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1199</fpage>&#x02010;<lpage>1207</lpage>.<pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref><ref id="jca21806-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jca21806-cit-0002">
<string-name>
<surname>Zhu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A novel coronavirus from patients with pneumoniain China, 2019</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>727</fpage>&#x02010;<lpage>733</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="jca21806-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0003">
<collab collab-type="authors">World Health Organization Press Conference</collab>
. The World Health Organization (WHO) has officially named the disease caused by the novel coronavirus as COVID&#x02010;19. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel%2010coronavirus%20102019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>. Accessed on April 17, <year>2020</year>.</mixed-citation></ref><ref id="jca21806-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jca21806-cit-0004">
<string-name>
<surname>Gorbalenya</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Baric</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Severe acute respiratory syndrome&#x02010;related coronavirus: the species and its viruses &#x02010; a statement of the Coronavirus Study Group</article-title>. <source xml:lang="en">bioRxiv</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.02.07.937862</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jca21806-cit-0005">
<string-name>
<surname>Guan</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Comorbidity and its impact on 1590 patients with Covid&#x02010;19 in China: a nationwide analysis</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2020</year>;<volume>55</volume>:<fpage>2000547</fpage>
<pub-id pub-id-type="doi">10.1183/13993003.00547-2020</pub-id>.<pub-id pub-id-type="pmid">32217650</pub-id></mixed-citation></ref><ref id="jca21806-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jca21806-cit-0006">
<string-name>
<surname>Graham</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Ambrosino</surname>
<given-names>DM</given-names>
</string-name>. <article-title>History of passive antibody administration forprevention and treatment of infectious diseases</article-title>. <source xml:lang="en">Curr Opin HIV AIDS</source>. <year>2015</year>;<volume>10</volume>:<fpage>129</fpage>&#x02010;<lpage>134</lpage>.<pub-id pub-id-type="pmid">25760933</pub-id></mixed-citation></ref><ref id="jca21806-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jca21806-cit-0007">
<string-name>
<surname>Bloch</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Shoham</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Deployment ofconvalescent plasma for the prevention and treatment of COVID&#x02010;19</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>2020</year>;<volume>130</volume>:<fpage>2757</fpage>&#x02010;<lpage>2765</lpage>. <pub-id pub-id-type="doi">10.1172/JCI138745</pub-id>.<pub-id pub-id-type="pmid">32254064</pub-id></mixed-citation></ref><ref id="jca21806-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jca21806-cit-0008">
<string-name>
<surname>Soo</surname>
<given-names>YO</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Retrospective comparison of convalescent plasma with continuinghigh&#x02010;dose methylprednisolone treatment in SARS patients</article-title>. <source xml:lang="en">Clin Microbiol Infect</source>. <year>2004</year>;<volume>10</volume>:<fpage>676</fpage>&#x02010;<lpage>678</lpage>.<pub-id pub-id-type="pmid">15214887</pub-id></mixed-citation></ref><ref id="jca21806-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jca21806-cit-0009">
<string-name>
<surname>Yeh</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Chiueh</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Siu</surname>
<given-names>LK</given-names>
</string-name>, et al. <article-title>Experience of using convalescent plasma for severeacute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2005</year>;<volume>56</volume>:<fpage>919</fpage>&#x02010;<lpage>922</lpage>.<pub-id pub-id-type="pmid">16183666</pub-id></mixed-citation></ref><ref id="jca21806-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jca21806-cit-0010">
<string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Soo</surname>
<given-names>YO</given-names>
</string-name>, et al. <article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title>. <source xml:lang="en">Eur J Clin Microbiol Infect Dis</source>. <year>2005</year>;<volume>24</volume>:<fpage>44</fpage>&#x02010;<lpage>46</lpage>.<pub-id pub-id-type="pmid">15616839</pub-id></mixed-citation></ref><ref id="jca21806-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jca21806-cit-0011">
<string-name>
<surname>van Griensven</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>de Lamballerie</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Evaluation of convalescent plasma for Ebola virus disease in Guinea</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2016</year>;<volume>374</volume>:<fpage>33</fpage>&#x02010;<lpage>42</lpage>.<pub-id pub-id-type="pmid">26735992</pub-id></mixed-citation></ref><ref id="jca21806-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jca21806-cit-0012">
<string-name>
<surname>Ko</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Seok</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>SY</given-names>
</string-name>, et al. <article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirusinfection: a single centre experience</article-title>. <source xml:lang="en">Antivir Ther</source>. <year>2018</year>;<volume>23</volume>:<fpage>617</fpage>&#x02010;<lpage>622</lpage>.<pub-id pub-id-type="pmid">29923831</pub-id></mixed-citation></ref><ref id="jca21806-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jca21806-cit-0013">
<string-name>
<surname>Arabi</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Hajeer</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Luke</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Feasibility of using convalescent plasma immunotherapy for MERS&#x02010;CoV infection, Saudi Arabia</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume>:<fpage>1554</fpage>&#x02010;<lpage>1561</lpage>.<pub-id pub-id-type="pmid">27532807</pub-id></mixed-citation></ref><ref id="jca21806-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jca21806-cit-0014">
<string-name>
<surname>Shen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Treatment of 5 critically ill patients with COVID&#x02010;19 with convalescent plasma</article-title>. <source xml:lang="en">Jama</source>. <year>2020</year> Mar 27;<volume>323</volume>:<fpage>1582</fpage>
<pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jca21806-cit-0015">
<string-name>
<surname>Duan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Effectiveness of convalescent plasmatherapy in severe COVID&#x02010;19 patients</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>(<issue>17</issue>):<fpage>9490</fpage>&#x02013;<lpage>9496</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id>.<pub-id pub-id-type="pmid">32253318</pub-id></mixed-citation></ref><ref id="jca21806-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0016">
<collab collab-type="authors">FDA</collab>
. Investigational covid&#x02010;19 convalescent plasma&#x02014;emergency INDs. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines%2010blood%2010biologics/investigational%2010new%2010drug%2010ind%2010or%2010device%2010exemption%2010ideprocess%2010cber/investigational%2010covid%201019%2010convalescent%2010plasma%2010emergency%2010inds">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds</ext-link>. Accessed May 11, <year>2020</year>.</mixed-citation></ref><ref id="jca21806-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0017">
<collab collab-type="authors">Turkish Ministry of Health</collab>
. <ext-link ext-link-type="uri" xlink:href="https://dosyamerkez.saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0">https://dosyamerkez.saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0</ext-link>. Accessed April 17, <year>2020</year>.</mixed-citation></ref><ref id="jca21806-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jca21806-cit-0018">
<string-name>
<surname>van Erp</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Luytjes</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ferwerda</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>van Kasteren</surname>
<given-names>PB</given-names>
</string-name>. <article-title>Fc&#x02010;mediated antibody effector functions during respiratory syncytial virus infection and disease</article-title>. <source xml:lang="en">Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>548</fpage>.<pub-id pub-id-type="pmid">30967872</pub-id></mixed-citation></ref><ref id="jca21806-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jca21806-cit-0019">
<string-name>
<surname>Gunn</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Karim</surname>
<given-names>MM</given-names>
</string-name>, et al. <article-title>A role for fc function in therapeutic monoclonal antibody&#x02010;mediated protection against Ebola virus</article-title>. <source xml:lang="en">Cell Host Microbe</source>. <year>2018</year>;<volume>24</volume>:<fpage>221</fpage>&#x02010;<lpage>233</lpage>.<pub-id pub-id-type="pmid">30092199</pub-id></mixed-citation></ref><ref id="jca21806-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jca21806-cit-0020">
<string-name>
<surname>Ozma</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Maroufi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Khodadadi</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Clinical manifestation, diagnosis, prevention and control of SARS&#x02010;CoV&#x02010;2 (COVID&#x02010;19) during the outbreak period</article-title>. <source xml:lang="en">Infez Med</source>. <year>2020</year>;<volume>28</volume>:<fpage>153</fpage>&#x02010;<lpage>165</lpage>.<pub-id pub-id-type="pmid">32275257</pub-id></mixed-citation></ref><ref id="jca21806-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jca21806-cit-0021">
<string-name>
<surname>Amanat</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chromikova</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>A serological assay to detect SARS&#x02010;CoV&#x02010;2 seroconversion in humans</article-title>. <source xml:lang="en">medRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.03.17.20037713</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jca21806-cit-0022">
<string-name>
<surname>Okba</surname>
<given-names>NMA</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 specific antibody responses in COVID&#x02010;19 patients</article-title>. <source xml:lang="en">medRxiv</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.18.20038059</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jca21806-cit-0023">
<string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Development and clinical application of a rapid IgM&#x02010;IgG combined antibody test for SARS&#x02010;CoV&#x02010;2 infection diagnosis</article-title>. <source xml:lang="en">J Med Virol</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1002/jmv.25727</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jca21806-cit-0024">
<string-name>
<surname>Guo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Profiling early humoral response to diagnose novel coronavirus disease (COVID&#x02010;19)</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year> pii: ciaa310. <pub-id pub-id-type="doi">10.1093/cid/ciaa310</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jca21806-cit-0025">
<string-name>
<surname>Duan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>The Feasibility of Convalescent Plasma Therapy in Severe COVID&#x02010;19 Patientss:a Pilot Study</article-title>. <source xml:lang="en">medRxiv</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.16.20036145</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jca21806-cit-0026">
<string-name>
<surname>Zhao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Antibody responses to SARS&#x02010;CoV&#x02010;2 in patients of novel coronavirus disease 2019</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1093/cid/ciaa344</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jca21806-cit-0027">
<string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Scharff</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Return to the past: the case for antibody&#x02010;basedtherapies in infectious diseases</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>1995</year>;<volume>21</volume>:<fpage>150</fpage>&#x02010;<lpage>161</lpage>.<pub-id pub-id-type="pmid">7578724</pub-id></mixed-citation></ref><ref id="jca21806-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jca21806-cit-0028">
<string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>. <article-title>Passive antibody administration (immediate immunity) as aspecific defense against biological weapons</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2002</year>;<volume>8</volume>:<fpage>833</fpage>&#x02010;<lpage>841</lpage>.<pub-id pub-id-type="pmid">12141970</pub-id></mixed-citation></ref><ref id="jca21806-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0029">
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=convalescent%2Bplasma">https://clinicaltrials.gov/ct2/results?cond=convalescent+plasma</ext-link>. Accessed May 11, 2020.</mixed-citation></ref><ref id="jca21806-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jca21806-cit-0030">
<string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pirofski</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Antibody&#x02010;mediated regulation of cellular immunityand the inflammatory response</article-title>. <source xml:lang="en">Trends Immunol</source>. <year>2003</year>;<volume>24</volume>:<fpage>474</fpage>&#x02010;<lpage>478</lpage>.<pub-id pub-id-type="pmid">12967670</pub-id></mixed-citation></ref><ref id="jca21806-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jca21806-cit-0031">
<string-name>
<surname>Casadevall</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Scharff</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Serum therapy revisited: animal models of infection and development of passive antibody therapy</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>1994</year>;<volume>38</volume>:<fpage>1695</fpage>&#x02010;<lpage>1702</lpage>.<pub-id pub-id-type="pmid">7985997</pub-id></mixed-citation></ref><ref id="jca21806-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0032">
<string-name>
<surname>Rijnders</surname>
<given-names>B.</given-names>
</string-name> Convalescent plasma as therapy for Covid&#x02010;19 severe SARS&#x02010;CoV&#x02010;2 disease (CONCOVID study) (ConCoVid&#x02010;19). <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrialsgov</ext-link> Identifier: NCT04342182</mixed-citation></ref><ref id="jca21806-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jca21806-cit-0033">
<string-name>
<surname>Hendrickson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Hillyer</surname>
<given-names>CD</given-names>
</string-name>. <article-title>Noninfectious serious hazards of transfusion</article-title>. <source xml:lang="en">Anesth Analg</source>. <year>2009</year>;<volume>108</volume>:<fpage>759</fpage>&#x02010;<lpage>769</lpage>.<pub-id pub-id-type="pmid">19224780</pub-id></mixed-citation></ref><ref id="jca21806-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jca21806-cit-0034">
<string-name>
<surname>Busch</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Bloch</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Kleinman</surname>
<given-names>S</given-names>
</string-name>. <article-title>Prevention of transfusion&#x02010;transmittedinfections</article-title>. <source xml:lang="en">Blood</source>. <year>2019</year>;<volume>133</volume>:<fpage>1854</fpage>&#x02010;<lpage>1864</lpage>.<pub-id pub-id-type="pmid">30808637</pub-id></mixed-citation></ref><ref id="jca21806-bib-0035"><label>35</label><mixed-citation publication-type="book" id="jca21806-cit-0035">
<collab collab-type="authors">AABB</collab>
. <source xml:lang="en">Standards for blood banks and transfusion services</source>. <publisher-loc>AABB</publisher-loc>: <publisher-name>Bethesda, MD</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="jca21806-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="jca21806-cit-0036">
<collab collab-type="authors">FDA</collab>
. Electronic Code of Federal Regulations: 630.30 Donation suitability requirements. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3</ext-link>. Updated March 17, 2020. Accessed March 19, <year>2020</year>.</mixed-citation></ref><ref id="jca21806-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jca21806-cit-0037">
<string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Detection of SARS&#x02010;CoV&#x02010;2 in different types of clinical specimens</article-title>. <source xml:lang="en">Jama</source>. <year>2020</year>;<volume>323</volume>(<issue>18</issue>):<fpage>1843</fpage>
<pub-id pub-id-type="doi">10.1001/jama.2020.3786</pub-id>.</mixed-citation></ref><ref id="jca21806-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jca21806-cit-0038">
<string-name>
<surname>Chang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>. <article-title>Severe acute respiratory SyndromeCoronavirus 2 RNA detected in blood donations</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2020</year>;<volume>26</volume>(<issue>7</issue>):<fpage>1631</fpage>&#x02013;<lpage>1633</lpage>. <pub-id pub-id-type="doi">10.3201/eid2607.200839</pub-id>.<pub-id pub-id-type="pmid">32243255</pub-id></mixed-citation></ref><ref id="jca21806-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jca21806-cit-0039">
<string-name>
<surname>Katzelnick</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Gresh</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Halloran</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>Antibody&#x02010;dependent enhancement of severe dengue disease in humans</article-title>. <source xml:lang="en">Science</source>. <year>2017</year>;<volume>358</volume>:<fpage>929</fpage>&#x02010;<lpage>932</lpage>.<pub-id pub-id-type="pmid">29097492</pub-id></mixed-citation></ref><ref id="jca21806-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jca21806-cit-0040">
<string-name>
<surname>Tetro</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Is COVID&#x02010;19 receiving ADE from other coronaviruses?</article-title>
<source xml:lang="en">Microbes Infect</source>. <year>2020</year>;<volume>22</volume>:<fpage>72</fpage>&#x02010;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32092539</pub-id></mixed-citation></ref></ref-list></back></article>